Literature DB >> 19029290

Characterization of fluorescent sterol binding to purified human NPC1.

Ronghua Liu1, Peihua Lu, Joseph W K Chu, Frances J Sharom.   

Abstract

Mutations in the NPC1 gene cause Niemann-Pick type C disease, which appears to result from a defect in intracellular cholesterol trafficking. NPC1 is a member of the resistance-nodulation-cell division (RND) permease superfamily and contains a sterol-sensing domain, yet its cellular function and the identity of its substrates remain unknown. FLAG-tagged human NPC1 was purified from NPC1-expressing Chinese hamster ovary cells by solubilization in 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (CHAPS), followed by affinity chromatography. Purified NPC1 in detergent solution appeared to be oligomeric as determined by gel filtration fast protein liquid chromatography and was photolabeled by an azido-cholesterol derivative. Fluorescent cholesterol analogs, including dehydroergosterol, cholestatrienol, and 22-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-23,24-bisnor-5-cholen-3beta-ol (NBD-cholesterol), displayed enhanced fluorescence upon binding to NPC1 and also resulted in saturable, concentration-dependent quenching of NPC1 intrinsic Trp fluorescence. The apparent binding affinity for these three sterols was in the 0.5-6 microm range. Binding of NBD-cholesterol to NPC1 at low detergent concentration (2 mm CHAPS) was of high apparent affinity (0.5-0.6 microm) and occurred rapidly (<1 min). However, binding of a BODIPY-labeled cholesterol derivative was very slow, requiring approximately 3 h to reach equilibrium. The apparent NBD-cholesterol binding affinity was greatly reduced at higher detergent concentration. The stoichiometry of NBD-cholesterol binding to NPC1 was approximately 1. Various sterols, including native cholesterol and 25-hydroxycholesterol, inhibited NBD-cholesterol binding, suggesting that they compete for binding to the protein. Dynamic quenching studies showed that bound NBD-cholesterol was almost completely shielded from the aqueous medium, suggesting that it is buried in a deep hydrophobic pocket in NPC1. The use of fluorescent cholesterol analogs provides novel information on the molecular properties of the sterol-binding site in the full-length NPC1 protein.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19029290     DOI: 10.1074/jbc.M803741200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Niemann-Pick type C 1 function requires lumenal domain residues that mediate cholesterol-dependent NPC2 binding.

Authors:  Maika S Deffieu; Suzanne R Pfeffer
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

Review 2.  NPC intracellular cholesterol transporter 1 (NPC1)-mediated cholesterol export from lysosomes.

Authors:  Suzanne R Pfeffer
Journal:  J Biol Chem       Date:  2019-02-01       Impact factor: 5.157

3.  Altered vitamin E status in Niemann-Pick type C disease.

Authors:  L Ulatowski; R Parker; C Davidson; N Yanjanin; T J Kelley; D Corey; J Atkinson; F Porter; H Arai; S U Walkley; D Manor
Journal:  J Lipid Res       Date:  2011-05-05       Impact factor: 5.922

4.  Human FABP1 T94A variant enhances cholesterol uptake.

Authors:  Huan Huang; Avery L McIntosh; Kerstin K Landrock; Danilo Landrock; Stephen M Storey; Gregory G Martin; Shipra Gupta; Barbara P Atshaves; Ann B Kier; Friedhelm Schroeder
Journal:  Biochim Biophys Acta       Date:  2015-02-27

Review 5.  A new player in the puzzle of filovirus entry.

Authors:  Judith M White; Kathryn L Schornberg
Journal:  Nat Rev Microbiol       Date:  2012-04-11       Impact factor: 60.633

Review 6.  Niemann-Pick C2 (NPC2) and intracellular cholesterol trafficking.

Authors:  Judith Storch; Zhi Xu
Journal:  Biochim Biophys Acta       Date:  2009-02-13

Review 7.  Intracellular sterol dynamics.

Authors:  Bruno Mesmin; Frederick R Maxfield
Journal:  Biochim Biophys Acta       Date:  2009-03-12

8.  The Niemann-Pick C1 and caveolin-1 proteins interact to modulate efflux of low density lipoprotein-derived cholesterol from late endocytic compartments.

Authors:  David Jelinek; Randy A Heidenreich; Robert A Orlando; William S Garver
Journal:  J Mol Biochem       Date:  2014-02-28

9.  Cholesterol lowering drug may influence cellular immune response by altering MHC II function.

Authors:  Koushik Roy; Moumita Ghosh; Tuhin Kumar Pal; Saikat Chakrabarti; Syamal Roy
Journal:  J Lipid Res       Date:  2013-09-13       Impact factor: 5.922

10.  The National Niemann-Pick Type C1 Disease Database: correlation of lipid profiles, mutations, and biochemical phenotypes.

Authors:  William S Garver; David Jelinek; F John Meaney; James Flynn; Kathleen M Pettit; Glen Shepherd; Randall A Heidenreich; Cate M Walsh Vockley; Graciela Castro; Gordon A Francis
Journal:  J Lipid Res       Date:  2009-09-09       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.